For the Inventor, By the Inventor

Enter assignee name

Beerse, Belgium

Janssen Pharmaceutica Nv

Calculating rank

USPTO Granted Patents = 2,101

% Expired Patents = 32.7

CIPO Patents = 193

EPO Patents = 699

Trademarks = 2

Forward Citations = 11,688

Loading Chart...

Loading Chart...

1,976 inventors (with patents filed for the assignee):

Jan Heeres (103 out of 124 patents)

Lieven Meerpoel (85 out of 97 patents)

Zhihua Sui (78 out of 108 patents)

4. Mark J Macielag (75 out of 91 patents)

5. James Patrick Edwards (73 out of 165 patents)

6. Frans E Janssens (72 out of 77 patents)

7. Kristof Van Emelen (50 out of 50 patents)

8. Patrick René Angibaud (49 out of 65 patents)

9. Marc Gaston Venet (49 out of 54 patents)

10. Peter J Connolly (48 out of 70 patents)

11. Yue-Mei Zhang (48 out of 49 patents)

12. Jérôme Emile Georges Guillemont (45 out of 49 patents)

13. Michael Anthony Letavic (45 out of 65 patents)

14. Curt A Dvorak (44 out of 49 patents)

15. Jennifer Diane Venable (44 out of 52 patents)

Core Competencies:

Adenosine A2a Receptor

Monoacylglycerol Lipase

Orexin Receptor

IL-17 Modulators

Factor XIa Inhibitors

Btk Inhibitors

Cognitive Decline

Bruton's Tyrosine Kinase

FGFR Inhibitors

Antibodies

Prostate Cancer

Depression Treatment

2,101 patents: Sort by Forward Citations

1. 12763184 - Clinical supply packs with electronic labeling (2026-10-13),

2. 12754116 - Biorelevant dissolution media (2026-10-06),

3. 12734180 - Treatment of prostate cancer with a combination of abiraterone acetate, niraparib tosylate monohydrate and prednisone (2026-09-15),

4. 12715878 - Tricyclic pyrimidines as cyclin-dependent kinase 7 (CDK7) inhibitors (2026-08-25),

5. 12708717 - CAP FOR AN INJECTION DEVICE (2026-08-18),

6. 12708641 - BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E (2026-08-18),

7. 12702766 - Drug delivery devices with reusable components and disposable components (2026-08-11),

8. D1137640 - Intranasal drug delivery device (2026-07-28),

9. 12691112 - FGFR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF UROTHELIAL CARCINOMA (2026-07-28),

10. 12679839 - Cyclin-dependent kinase 7 (CDK7) non-covalent inhibitors (2026-07-14),

11. 12678564 - Training devices and methods for simulating intranasal drug delivery (2026-07-14),

12. 12678498 - FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER (2026-07-14),

13. 12661460 - Drug delivery devices with a spinning nozzle (2026-06-23),

14. 12653755 - Esketamine formulations and methods for preparation and storage (2026-06-16),

15. 12622910 - Inhibitors of Bruton's tyrosine kinase and methods of their use (2026-05-12),

Company Overview

Janssen Pharmaceutica NV, headquartered in Beerse, Belgium, is a prominent player in the pharmaceutical industry, focusing on the development of innovative therapies. The company specializes in a range of core technologies, including modulators targeting the adenosine A2a receptor, monoacylglycerol lipase, and orexin receptor, as well as IL-17 and Factor XIa inhibitors. Janssen is committed to addressing cognitive decline and advancing treatments through its expertise in Bruton's tyrosine kinase and related pathways.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

2,101 Patents

#1 in Beerse

#1 in Belgium

#480 in the World

Beerse, Belgium

Janssen Pharmaceutica Nv

Forward Citations = 11,688

1,976 inventors:

Jan Heeres (103 out of 124 patents)

Lieven Meerpoel (85 out of 97 patents)

Zhihua Sui (78 out of 108 patents)

4. Mark J Macielag (75 out of 91 patents)

5. James Patrick Edwards (73 out of 165 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Janssen Pharmaceutica Nv. Retrieved from https://idiyas.com/company/janssen-pharmaceutica-nv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…